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Summary 
The epidemiology of laboratory-confirmed RSV infections in young children has not recently been 
described in England, and is an essential step in identifying optimal target groups for future licensed RSV 
vaccines. We used two laboratory surveillance systems to examine the total number and number of 
positive RSV tests in children less than five years old in England from 2010- 2014.  We derived odds 
ratios with 95% confidence intervals comparing children by birth month, using multivariable logistic 
regression models adjusted for age, season and sex.  47% of RSV tests (29,851/63,827) and 57% 
(7,405/13,034) of positive results in children under five years old were in infants younger than six 
months.  Moreover, 38% (4,982/13,034) of positive results were in infants younger than three months.  
Infants born in September, October and November had the highest odds of a positive RSV test during 
their first year of life compared to infants born in January (OR=2.1 (95% CI 1.7, 2.7), OR=2.4 (95% CI 2.1, 
2.8) and OR=2.4 (95% CI 2.1, 2.7), respectively).   Our results highlight the importance of young age and 
birth month near the beginning of RSV season to the risk of laboratory confirmed RSV infection.   Future 
control measures should consider protection for these groups. 
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Introduction 
Respiratory syncytial virus (RSV) is a major cause of hospitalisation with lower respiratory tract 
infections in young children worldwide (1).  RSV infection in early life is associated with development of 
long term respiratory morbidity including asthma and recurrent wheezing (1).  In developing countries, 
RSV is also an important cause of childhood mortality (2).  Risk factors for severe RSV infection resulting 
in hospitalisation have been identified such as prematurity, chronic lung disease and congenital heart 
disease (3).  However, it has been estimated that four fifths of RSV-associated hospitalisations in infancy 
occur in previously healthy infants born at term, with young age a significant risk factor for severe RSV 
infection (4).  Consequently, RSV is a high priority for vaccine development, with several vaccines now in 
phase two clinical trials (5).  Potential target groups for a future RSV vaccine have been identified 
including pregnant women, young infants and children 6-24 months old, although further work is 
needed to determine the optimal age and target groups for a potential future licensed vaccine (6).  
Birth in close proximity to the beginning of RSV season has been shown to be a significant risk factor for 
RSV-associated hospitalisation in infancy (7–11).  However, these studies rely solely on clinical 
diagnoses, are based outside of the UK or are of small study populations (7).  With various causative 
agents of upper and lower respiratory tract infections and testing only carried out in a minority of cases, 
relying on clinical diagnoses without laboratory confirmation of RSV may bias any observed associations 
between patient characteristics and severe RSV infection due to potential low specificity (12–14).  Using 
laboratory-confirmed RSV infection has the advantage of being highly specific, and is a starting point 
from which estimates of the burden of RSV in England can be calculated.  The epidemiology of 
laboratory-confirmed RSV infection in infants and young children in England has not recently been 
described (13–15).   
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This study uses laboratory surveillance data to examine the relationship between laboratory-confirmed 
RSV infection and age and birth month in children less than five years old in England, to contribute to 
the identification of optimal target groups for any potential future licensed vaccine.   
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Methods 
Data sources 
The Respiratory DataMart System (RDS) is a surveillance system established by Public Health England 
(PHE) during the 2009 influenza A(H1N1) pandemic to collect both positive and negative laboratory 
results for major respiratory viruses (16).  RSV test results through this system are available from 2010 
onwards.  Fourteen Public Health England (PHE) and National Health Service (NHS) laboratories in 
England currently submit data to the RDS through automatic electronic outputs.  The majority of tested 
samples have been collected from hospitals (16).  Respiratory samples are tested for a range of 
respiratory viral pathogens including RSV, influenza A and B, parainfluenza, rhinovirus and human 
metapneumovirus (hMPV) using real-time reverse transcription polymerase chain reaction (rRT-PCR), 
and adenovirus using real-time PCR.  Though not all participating laboratories test for all viruses, all test 
for RSV.  In RDS, de-duplication is carried out during the data importation process; samples taken from 
the same individual within a six-week period are grouped as one record to capture a single episode of 
infection in an individual (16).  We included data from 13 of the 14 laboratories with consistent 
reporting of RSV results during the study period:  Birmingham, Bristol, Barts and The London, 
Cambridge, Leeds, Leicester, Manchester, Newcastle, Nottingham, Royal Free Hospital, Southampton, 
Truro and the Reference Laboratory at PHE Colindale.  Weekly data was extracted from calendar week 
27 in 2010 to week 26 in 2014 in children less than five years of age.  The extracted data include 
information on patient’s date of birth, sex, date of sample, and whether the RSV laboratory test was 
positive for RSV, negative for RSV but positive for another respiratory virus, or negative for all viruses 
including RSV.   
We compared the RDS study population to the national laboratory surveillance system, LabBase2, also 
held by PHE.  LabBase2 is a long established laboratory surveillance system that covers England, Wales 
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and Northern Ireland, but only includes records of positive RSV tests.  Positive RSV test data from 
laboratories submitting to the RDS are also submitted to the national LabBase2 database.  Several 
different types of laboratory tests are used for diagnosis of RSV infection by laboratories contributing to 
LabBase2, with the majority using genome or antigen detection methods. Similarly to the RDS, de-
duplication is carried out during the data importation process; samples taken from the same individual 
within a six-week period are assigned a unique identifier to capture a single episode of infection in an 
individual.  We extracted all respiratory samples from LabBase2 from children less than five years of age 
tested in all laboratories in England from week 27 in 2010 to week 26 in 2014, and only included the first 
sample of each episode of infection in this analysis. 
Statistical analysis 
The total number of RSV tests (positive and negative) in the RDS extract, the number of positive RSV 
tests in the RDS extract and the number of positive episodes in the LabBase2 extract were summarised 
by age, month of birth, year (between week 27 2010 and  week 26 2014) and sex.  We calculated the 
RSV positivity rate as the number of RSV positive tests divided by the total number of RSV tests in the 
RDS extract by age, month of birth, sex and year.  We defined RSV season onset as the first of two 
consecutive weeks in which the mean percentage of samples testing positive for RSV in the RDS was 
≥10%, and the end of RSV season as the last of two consecutive weeks in which the mean percentage of 
samples testing positive for RSV was ≥10%, a method which has been used in previous studies (17)(18).   
We used multivariable logistic regression models to estimate the odds of a positive result (if tested for 
RSV) by birth month, using the RDS extract.  Age group (0, 1, 2, 3 and 4 years), sex (male, female and 
unknown) and year (2010-2011, 2011-2012, 2012-2013, 2013-2014) were investigated as potential 
confounders and were added to the model in a forward stepwise manner.  We also included an 
interaction term between age group and birth month.  We used likelihood ratio tests to determine 
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whether the inclusion of a variable significantly improved the fit of the model; a likelihood ratio test p-
value of <0.05 was considered significant.  Robust standard errors were used to allow for clustering by 
laboratory.  Infants born in January were used as the baseline group.  
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Results 
Characteristics of the study population are shown in Table 1.  In the RDS there was an average of 15,986 
tests and 3,259 RSV positives per year in children less than five years of age during the study period.  
Laboratory-confirmed RSV positivity showed a clear and consistent seasonal pattern; RSV season onset 
was in October each year (ranging from calendar week 41 to 43) during the study period and the end of 
RSV season ranged from January to March (week 4 to week 10).  Overall testing peaked during 
December in each RSV season of the four years studied (Figure 1).  The week with the highest 
proportion of positive RSV laboratory tests in children less than five years of age each season was week 
48 in 2010-2011 (42% positive), week 1 in 2011-2012 (55% positive), and week 49 in 2012-2013 and 
2013-2014 (52% and 55% positive, respectively).  Of the four years included in the study, the highest 
number of RSV laboratory tests was carried out during the 2010-2011 RSV season.  Of the RSV positive 
tests in the RDS during the study period (n=13,034), 16% were also positive for at least one other 
respiratory virus.  Of the RSV negative tests in the RDS during the study period (n=50,793), 41% were 
positive for at least one other respiratory virus. 
The results by age, birth month and sex were very similar in the RDS and LabBase2 extracts (Table 1).  
The RDS results demonstrated that both the total number of tests and the number of positive tests 
decreased with increasing age (Figure 2).   76% (9,933/13,034) of RSV positive tests in children less than 
five years of age over the study period were in infants less than one year of age, whereas only 2% 
(214/13,034) were in in children aged four years.  Moreover, 47% of tests (29,851/63,827) and 57% 
(7,405/13,034) of positives in children less than five years of age over the study period were in infants 
less than six months of age.  The number of RSV positives peaked at age one month (n=2,198).  Infants 
aged 1, 2 and 3 months had the highest rate of RSV positivity: 29% (2,198/7,551) and 29% (1,507/5,194) 
and 27% (996/3,697) tested positive for RSV, respectively.  The highest number of tests was in infants 
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aged less than one month (n=7,722).  Infants less than one year of age who were born in September, 
October and November had the highest number and proportion of positive test results (Table 1).   In 
LabBase2, 82% (25,283/30,669) of positive results in children less than five years of age over the study 
period were in infants less than one year of age; only 1% of tests (251/30,669) were in children aged 
four years.  The number of RSV positive tests also peaked at age one month (n=5,326).  13% 
(3,297/25,283) of infants with a positive RSV test in their first year of life recorded in LabBase2 were 
born in September, 16% (4,088/25,283) were born in October and 15% (3,743/25,283) were born in 
November.  In both datasets the sex ratio (M:F) was 1.3:1.   
The best fitting multivariable logistic regression model included sex, calendar year, age group and birth 
month as well as an age group:birth month interaction term.   Infants aged less than one year of age 
born in September (OR=2.1, 95% CI 1.7, 2.7), October (OR=2.4, 95% CI 2.1, 2.8) or November (OR=2.4, 
95% CI 2.1, 2.7) had the highest odds of a positive result if tested for RSV in the first year of life 
compared to infants born in January (Figure 3).  The effect of birth month on odds of a RSV positive test 
result decreased with increasing age (Figure 4).  For example, infants aged four years born in September 
(OR=0.4, 95% CI 0.3, 0.6) and infants aged four years born in January (OR=0.4, 95% CI 0.3, 0.6) had the 
same odds of a positive result.  
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Discussion 
This study shows that a significant proportion of laboratory-confirmed RSV infections in England 
recorded in two laboratory surveillance databases from 2010 -2014 were in infants younger than six 
months old.  In both datasets, there was a peak in RSV positive tests in infants aged one month.  RSV 
circulation was very consistent in timing each year, with a three week range in season onset over the 
study period.  In addition, infants born near the beginning of an RSV season had significantly increased 
odds of a positive result if tested for RSV during the first year of life.   
A strength of our study is the use of laboratory confirmed RSV infection rather than clinically diagnosed 
RSV.  Using clinical diagnoses of RSV infection may include misclassification of diagnoses when 
laboratory tests were not carried out, as specific respiratory viral aetiologies cannot be differentiated 
clinically (19,20).  The use of clinical diagnoses alone may therefore lead to bias in associations between 
patient characteristics and RSV infection.  However, a limitation of our study is that no clinical 
information on the individuals tested was available in either dataset.  The majority of RSV records in the 
RDS and LabBase2 are from hospitalised patients (16), and it is likely that only severe or complex cases 
requiring hospital admission will require laboratory confirmation of RSV infection as it would usually be 
unnecessary to investigate mild infection for the presence of RSV.  However, without clinical information 
it is not possible to confirm whether or not this assumption is correct. In addition, the vast majority of 
tests in both RDS and LabBase2 were carried out on young children (less than one year). It is therefore 
possible that differences in testing according to age means that RSV is less likely to be picked up in older 
children.  Linkage between administrative hospital data and laboratory data would allow analysis of the 
potential association between clinical presentation, patient characteristics, the probability of being 
tested, and RSV positivity.  
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The considerable number of tests and RSV positive results in infants younger than six months of age and 
the peak in number and percentage of positive RSV tests in infants aged one month is consistent with 
existing literature that reports age under six months as a significant risk factor for severe RSV infection 
(21) and a peak in RSV bronchiolitis at age one month (12)(22).  Young infants have been a  high priority 
for vaccination due to the serious complications and subsequent morbidity that can occur following RSV 
infection in early life (6).  However, young infants are at risk of enhanced disease following vaccination 
as demonstrated during testing of the first candidate vaccine, formalin inactivated RSV, in the 1960s (6).  
The immaturity of the immune system and significant heterogeneity in the presence of maternal 
antibodies also present major challenges to vaccine development for this target group (23).  
Nonetheless, a World Health Organisation (WHO) consultation in early 2015 on the development of RSV 
vaccines suggests it is likely that an RSV vaccine will be available commercially within 5-10 years (24), as 
major advances in the understanding of the biology of RSV and innovations in immunogen design have 
resulted in a number of promising potential vaccine candidates in clinical trials (25).  Our results 
highlight the importance of developing optimal strategies to prevent disease in young infants with these 
potential future vaccines. 
Our analysis found RSV circulation to be highly consistent in timing each year, with only a three week 
range in season onset over the study period.  The large peak in infants being tested for RSV during 2010-
2011 can be attributed to the intense influenza season during this first post-pandemic winter period, as 
the RDS holds records of the results of samples tested simultaneously for multiple respiratory viruses 
including influenza and RSV (16)(26).  The large number of tests performed outside of the RSV season 
can also be attributed to testing for a range of respiratory viruses.  The consistency between results 
from the RDS and LabBase2 suggest generalisability of the RDS results to the long established national 
surveillance system. 
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Our finding that birth in months September to December was associated with increased odds of a 
positive result if tested for RSV in the first year of life in England supports the results of previous studies 
that show birth around the beginning of RSV season is a risk factor for RSV-associated hospitalisation (7–
9,11).  Several of these previous studies investigating month of birth as a risk factor for RSV-associated 
hospitalisation were limited by sample size and all based outside of the UK.  The largest study was 
carried out in the US and suggests children born during December and January had a 2- and 3-fold 
higher risk, respectively, of RSV-confirmed hospitalisation during infancy than those born in July, though 
these cases were identified by International Classification of Diseases (Ninth Revision) codes only (7).  
The increased risk of severe RSV infection in infants born close to the beginning of RSV season is likely 
due to these infants having a longer exposure to RSV at a young age in combination with lower levels of 
maternal antibodies during the beginning of RSV season and immaturity of the lungs (21).  The exact 
birth months with the highest risk of severe RSV infection in infancy varies between countries due to 
differences in the timing of RSV season, which highlights the importance of country-specific 
epidemiology studies including birth month as a potential risk factor when analysing severe RSV 
infection.   
This study highlights the importance of young age (less than six months) and birth near the beginning of 
RSV season in risk of laboratory confirmed RSV infection.  Future vaccination programmes and other 
interventions should ensure protection for these groups is considered.   
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Table 1.  Total number of tests (Respiratory DataMart System; RDS), number of respiratory syncytial 
virus (RSV)-positive tests (RDS), RSV positivity rate (RDS) and number of RSV positive tests (LabBase2) in 
children <5 years of age from week 27 (2010) to week 26 (2014) by sex, age, birth month if tested for 
RSV in the first year of life, and year (week 27 - week 26). 
 Respiratory DataMart System   LabBase2 
 Total tests 
N (%) 
RSV positive 
N (%) 
RSV positivity 
rate 
 RSV positive 
N (%) 
Total 63,827 13,034 20%  30,669 
      
Sex      
Male 31,278 (49%) 6,165 (47%) 20%  17,050 (56%) 
Female 23,577 (37%) 4,848 (37%) 21%  13,332 (43%) 
Unknown 8,970 (14%) 2,021 (16%) 23%  287 (1%) 
Sex ratio (M:F) 1.3:1 1.3:1   1.3:1 
      
Age      
<3 months 20,467 (32%) 4,982 (38%) 24%  12,641 (41%) 
3-5 months 9,384 (15%) 2,423 (19%) 26%  6,526 (21%) 
6-11 months 11,712 (18%) 2,528 (19%) 22%  6,116 (20%) 
1 year 10,439 (16%) 1,815 (14%) 17%  3,703 (12%) 
2 years 4,905 (8%) 670 (5%) 14%  922 (3%) 
3 years 3,929 (6%) 402 (3%) 10%  510 (2%) 
4 years 2,991 (5%) 214 (2%) 7%  251 (1%) 
      
Birth month (if <1 
year old)1 
     
January 3,271 (8%) 586 (6%) 18%  1,384 (5%) 
February  2,774 (7%) 404 (4%) 15%  994 (4%) 
March 2,970 (7%) 436 (4%) 15%  1,066 (4%) 
April 2,818 (7%) 448 (5%) 16%  1,132 (4%) 
May 3,038 (7%) 525 (5%) 17%  1,344 (5%) 
June 3,056 (7%) 646 (7%) 21%  1,519 (6%) 
July 3,173 (8%) 700 (7%) 22%  1,906 (8%) 
August 3,484 (8%) 906 (9%) 26%  2,484 (10%) 
September 3,833 (9%) 1,210 (12%) 32%  3,297 (13%) 
October 4,626 (11%) 1,593 (16%) 34%  4,088 (16%) 
November 4,575 (11%) 1,565 (16%) 34%  3,743 (15%) 
December 3,945 (9%) 914 (9%) 23%  2,326 (9%) 
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Year       
2010-2011 19,751 (31%) 4,103 (31%) 21%  8,327 (27%) 
2011-2012 14,804 (23%) 2,919 (22%) 20%  7,228 (24%)  
2012-2013 15,021 (24%) 3,013 (23%) 20%  7,495 (24%) 
2013-2014 14,251 (22% 2,999 (23%) 21%  7,619 (25%) 
1 Percentage denominator is the total number in infants <1 year old [i.e. Total tests (RDS) = 41,563, RSV 
positive (RDS) = 9,933 and RSV positive (LabBase2) = 25,283] 
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Figure 1.  Total number (blue) and number of positive (red) respiratory syncytial virus tests in children 
aged <5 year recorded in the Respiratory DataMart System from week 27 (2010) to week 26 (2014), 
over time. 
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Figure 2.  Total number (red) and number of positive (green) respiratory syncytial virus tests in 
children aged <5 years recorded in the Respiratory DataMart System from week 27 (2010) to week 26 
(2014), by age in months. 
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Figure 3.  Odds ratios and 95% confidence intervals (CI) from final multiple logistic regression model 
using Respiratory DataMart System data to compare odds of a positive result if tested for respiratory 
syncytial virus by birth month, showing results for infants aged <1 year only. Infants born in January 
are the baseline group. 
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Figure 4. Odds ratios from final multiple logistic regression model using Respiratory DataMart System 
data to compare odds of a positive result if tested for respiratory syncytial virus by birth month, 
stratified by age in years. Infants born in January are the baseline group. 
 
 
 
 
